, /PRNewswire/ -- According to the Skin Cancer Foundation, 90% of skin aging is caused by the sun, and even with proper SPF usage, harmful UV rays can still penetrate the skin. The root cause of visible skin discoloration and aging, these rays generate Reactive Oxygen Species [ROS], a subset of free radicals, ultimately triggering unwanted conditions such as premature aging, sagging, wrinkles, hyperpigmentation, and even skin cancer. As a leader in professional-grade skincare formulations, TOPIX Pharmaceuticals, Inc.
prioritizes investment in the latest technology, pioneering scientific discoveries to provide its dermatological partners the latest innovations in elevated skincare for their patients. Now, TOPIX Pharmaceuticals, Inc., in partnership with the , Center for Drug Design, are thrilled to present patented and proprietary molecule ProteXidineTM , a biomimetic decoy molecule that enhances the skin's innate ability to manage UV induced damage and inhibit the production of ROS.
The result of nearly a decade of research, the late breaking research and ongoing scientific trials mark a breakthrough in antioxidant technology to prevent premature aging. When the skin is exposed to ultraviolet rays, Cyclobutane Pyrimidine Dimers [CPDs] are formed, also known as thymine dimers in the DNA molecule. The accumulation of thymine dimers indicates UV damage in the skin, which is directly linked to an increased risk of skin cancer.
Beyond inhibiting the production of Reactive Oxygen S.
